A recent study has shed light on a potential dilemma for women planning pregnancy, especially those managing their weight and diabetes with GLP-1 medications. The research, conducted by a team from Mass General Brigham in Boston, suggests that stopping these drugs just before pregnancy could lead to increased health risks during pregnancy.
The Catch-22 of GLP-1 Medication and Pregnancy
GLP-1 medications, often used for weight loss and diabetes management, have seen a surge in use among women. However, the potential risks to the fetus during pregnancy are still unclear, leading to current recommendations to discontinue these drugs before or during pregnancy. But here's where it gets controversial: the study found that stopping GLP-1s might bring about its own set of hazards.
The research team, led by pediatric endocrinologist Dr. Jacqueline Maya, analyzed the medical records of nearly 1,800 pregnancies within the Mass General Brigham healthcare system between 2016 and 2025. Most of these pregnancies occurred among women with obesity, a group that often faces unique challenges in managing weight and health during pregnancy.
The study compared the outcomes of women who had received a GLP-1 prescription within three years before and up to 90 days after conception with those who hadn't. The results were eye-opening: women who stopped GLP-1s prior to pregnancy gained an average of 7.2 pounds more during their pregnancy than those who hadn't used GLP-1s. Moreover, the GLP-1 group had a 32% higher chance of unhealthy weight gain during pregnancy.
In terms of complications, the risks were even more pronounced. Women who discontinued GLP-1s before pregnancy had a 30% higher risk of developing diabetes during pregnancy, a 29% higher risk of blood pressure issues, and a 34% higher risk of preterm delivery. However, the study found no differences in the risks of high or low birth weight or Cesarean delivery.
While the study couldn't prove that GLP-1 discontinuation caused these excess pregnancy risks, it did highlight a significant association. Dr. Camille Powe, the study's senior author and an endocrinologist at Mass General Brigham, emphasized the need for further research to find ways to manage weight gain and reduce risks during pregnancy when stopping GLP-1 medications.
This study raises important questions for women with obesity who are considering pregnancy. Should they continue GLP-1 medications, potentially exposing their fetus to unknown risks, or should they stop, facing increased risks of weight gain and complications during pregnancy? It's a difficult choice, and more research is needed to provide clearer guidance.
What are your thoughts on this dilemma? Do you think the potential risks of GLP-1 medications during pregnancy outweigh the benefits of managing weight and diabetes before pregnancy? Share your insights and experiences in the comments below!
